$0.67
-0.01 (-1.76%)
Open$0.67
Previous Close$0.68
Day High$0.68
Day Low$0.66
52W High$1.82
52W Low$0.55
Volume—
Avg Volume64.2K
Market Cap8.20M
P/E Ratio—
EPS$-1.54
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+5,274.1% upside
Current
$0.67
$0.67
Target
$36.06
$36.06
$23.45
$36.06 avg
$38.88
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 540.3K | 1.10M | 1.13M |
| Net Income | -23,824,375 | 89.2K | 117.7K |
| Profit Margin | -4,409.1% | 8.1% | 10.4% |
| EBITDA | -24,982,891 | 177.4K | 182.1K |
| Free Cash Flow | — | 70.9K | 72.7K |
| Rev Growth | — | +5.3% | -7.0% |
| Debt/Equity | — | 0.17 | 0.19 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |